Global cancer surgery: Delivering safe, affordable, and timely cancer surgery Journal Article


Authors: Sullivan, R.; Alatise, O. I.; Anderson, B. O.; Audisio, R.; Autier, P.; Aggarwal, A.; Balch, C.; Brennan, M. F.; Dare, A.; D'Cruz, A.; Eggermont, A. M. M.; Fleming, K.; Gueye, S. M.; Hagander, L.; Herrera, C. A.; Holmer, H.; Ilbawi, A. M.; Jarnheimer, A.; Ji, J. F.; Kingham, T. P.; Liberman, J.; Leather, A. J. M.; Meara, J. G.; Mukhopadhyay, S.; Murthy, S. S.; Omar, S.; Parham, G. P.; Pramesh, C. S.; Riviello, R.; Rodin, D.; Santini, L.; Shrikhande, S. V.; Shrime, M.; Thomas, R.; Tsunoda, A. T.; van de Velde, C.; Veronesi, U.; Vijaykumar, D. K.; Watters, D.; Wang, S.; Wu, Y. L.; Zeiton, M.; Purushotham, A.
Article Title: Global cancer surgery: Delivering safe, affordable, and timely cancer surgery
Abstract: Surgery is essential for global cancer care in all resource settings. Of the 15·2 million new cases of cancer in 2015, over 80% of cases will need surgery, some several times. By 2030, we estimate that annually 45 million surgical procedures will be needed worldwide. Yet, less than 25% of patients with cancer worldwide actually get safe, affordable, or timely surgery. This Commission on global cancer surgery, building on Global Surgery 2030, has examined the state of global cancer surgery through an analysis of the burden of surgical disease and breadth of cancer surgery, economics and financing, factors for strengthening surgical systems for cancer with multiple-country studies, the research agenda, and the political factors that frame policy making in this area. We found wide equity and economic gaps in global cancer surgery. Many patients throughout the world do not have access to cancer surgery, and the failure to train more cancer surgeons and strengthen systems could result in as much as US$6·2 trillion in lost cumulative gross domestic product by 2030. Many of the key adjunct treatment modalities for cancer surgery-eg, pathology and imaging-are also inadequate. Our analysis identified substantial issues, but also highlights solutions and innovations. Issues of access, a paucity of investment in public surgical systems, low investment in research, and training and education gaps are remarkably widespread. Solutions include better regulated public systems, international partnerships, super-centralisation of surgical services, novel surgical clinical trials, and new approaches to improve quality and scale up cancer surgical systems through education and training. Our key messages are directed at many global stakeholders, but the central message is that to deliver safe, affordable, and timely cancer surgery to all, surgery must be at the heart of global and national cancer control planning. © 2015 Elsevier Ltd.
Keywords: cancer surgery; surgical technique; histopathology; review; cancer adjuvant therapy; cancer palliative therapy; aromatase inhibitor; cancer pain; cancer research; health care policy; health care quality; cost effectiveness analysis; health care cost; health care utilization; health economics; health insurance; narcotic analgesic agent; clinical study; surgical training; health care system; radiography; safety; perioperative period; cancer control; primary medical care; politics; health care access; community care; randomized controlled trial (topic); clinical trial (topic); health care management; scale up; investment; gross national product; human; priority journal
Journal Title: Lancet Oncology
Volume: 16
Issue: 11
ISSN: 1470-2045
Publisher: Elsevier Science, Inc.  
Date Published: 2015-09-01
Start Page: 1193
End Page: 1224
Language: English
DOI: 10.1016/s1470-2045(15)00223-5
PROVIDER: scopus
PUBMED: 26427363
DOI/URL:
Notes: Export Date: 2 November 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Murray F Brennan
    1059 Brennan
  2. T Peter Kingham
    618 Kingham